Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Hansa aims for secondary US listing ahead of FDA decision on kidney transplant therapy

21 August 2026 · By · Wire by Fusion42

Published

21 August 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 21 August 2026 · Fusion42 review

Hansa Biopharma has confidentially filed for a secondary US listing on Nasdaq ahead of the FDA's expected decision in December 2026 on its kidney transplant therapy imlifidase, potentially increasing its access to US biotech investors and expanding its commercial reach.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now pitch to US investors with Hansa expanding its listing to Nasdaq ahead of its FDA approval decision; that market is opening to you as a proven biotech with a pivotal kidney transplant therapy.

◆ Coverage

1 source · 21 Aug 2026

◆ Related on Wire

◆ Topics

Biotechus-listingfda-decisionbiotechkidney-transplantcapital-markets